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Abstract 
 Antibiotic-resistant bacterial infections pose a real and increasing threat to public 
health and welfare. As bacteria continue to develop and spread resistance to currently 
used antibiotics it is of the upmost importance to develop new classes of antibiotics to 
combat them. Deoxnybyomycin (DNM), which has been previously found to be 
efficacious against fluoroquinolone resistant bacteria including S. aureus, is one such 
antimicrobial compound, and its further derivatization is reported herein. 
 Derivatives of DNM had been previously synthesized possessing alkyl 
substitutions at four different positions. Described in Chapter 2 is the synthesis of 
several new DNM based compounds containing either previously unexplored polar 
functionality or new modifications to the five-membered ring. These compounds were 
tested against fluoroquinolone resistant and wild-type S. aureus, and the derivatives 
based on modifying the five-membered ring were found to maintain strong activity and 
selectivity against fluoroquinolone resistant bacteria possessing a S84L mutation in 
GyrA. The polar compounds were found to be less active against fluoroquinolone 
resistant S. aureus, but at least one was found to maintain a strong difference in 
selectivity.  
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Chapter 1. Introduction 
1.1 Antibiotic usage before the modern era 
The modern antibiotic era is often thought to begin with the discovery of penicillin 
by Alexander Fleming in 1928.1,2 However, human exposure to antibiotics goes back at 
least as far as 350-550CE as traces of tetracycline likely high enough to have a 
protective effect have been found in human bone samples with tissue sample 
suggesting low rates of infection.3,4 Additionally, antibiotics and antibiotic containing 
compounds have been utilized in traditional Chinese medicine, most famously 
artemisinin,5 but other compounds have been discovered in different herb mixtures.6 
The use of antibiotics in humans ultimately pales in comparison to the production and 
use of antibiotics in the terrestrial and marine biomes from which many current 
antibiotics are derived. Cyanobacterial communities producing antibacterials have been 
dated back as far as 3.5 billion years.7  
1.1.1 Ancient bacterial resistance mechanisms 
 As a result of the extensive history of antimicrobial use in the natural world, 
methods of resistance have evolved with all bacteria possessing genes capable of 
responding to foreign small molecules.8 As a result, the bacterial resistome is ancient 
and vast and serves as a large reservoir to facilitate gene transfer and eventual 
resistance to the use of antibiotics in the present era with many non-pathogenic species 
carrying extensively drug resistance conferring genes.9 These bacteria can facilitate the 
maintenance and spread of bacterial resistance genes. Plasmids encoding for the 
production of β-lactamases, which provide resistance against antibiotics such as 
penicillin and cephalosporin, have been found to be nearly 100 million years old.10 
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1.2 The threat of antibiotic resistance to human health 
 Since the beginning of the modern antibiotic era bacteria resistance has 
eventually emerged to all major classes of antibiotics.11 This has resulted in an epidemic 
in which each year roughly 25,000 EU and 23,000 US residents die as a result of 
infection from multidrug resistant bacteria.12,13 Unfortunately, human antibiotic 
consumption is strongly correlated with an increase in antibiotic resistance, leading to 
the scenario in which antibiotics eventually render themselves obsolete.14 As a result, 
the need to develop new antibiotics and, in particular, new antibiotics with orthogonal 
modes of action to current agents, is high and constantly increasing. 
Resistance mechanisms are often described in terms of “target” or “bullet”.2 The 
antibiotic, the bullet, can be modified to render it inactive, destroyed by enzymes, 
removed via efflux pumps or prevented from entering the cell at all through manipulation 
of the cell membrane. The target of the antibiotic can be modified to be insensitive to 
the antibiotic, replaced by another protein capable of fulfilling its function or otherwise 
protected to prevent the antibiotic from accessing it. Bacteria that are able to acquire 
these methods of resistance through either gene transfer or mutation are capable of 
resisting antibiotics and passing these methods on to other bacteria thus increasing the 
prevalence of resistance mechanisms in nature.15 
1.3 Deoxynybomycin as an antibiotic for fluoroquinolone resistant bacteria 
 Nybomycin (NM) was first identified and isolated from a streptomycete Missouri 
soil sample and wasfound to be active against S. aureus, M. smegmatis, and Bacillus 
species.16,17 During its chemical synthesis the compound deoxynybomycin (DNM, 
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Figure 1.1) was synthesized as an intermediate and eventually shown to be a natural 
product itself.18,19 Recently, DNM was recently shown to target fluoroquinolone resistant 
(FQR) MRSA by inhibiting the mutant DNA gyrase A,20,21 and was considerably more 
selective for the FQR S. aureus than the wild type, prompting an investigation into a 
possible new class of antibiotics that target resistance mechanisms. Until recently DNM 
lacked a practical synthetic route and issues with its low solubility confounded efforts to 
explore it further. In chapter 2 we will demonstrate how new derivatives with greater 
solubility have been synthesized addressing this low solubility.20 
 
 
 
 
Figure 1.1. Structures of Deoxynybomycin and Nybomycin 
 
1.3.1 Deoxnybomycin and floruoqinolone resistance 
 It is perhaps unsurprising that resistance to many natural product or 
semisynthetic antibiotics could develop in pathogenic bacteria due to the heavy 
selective pressure from the clinical use of antibiotics. These bacteria are able to draw 
not just on their own ability to evade antibiotics, but the bacterial resistome as well. 
Other bacteria may have evolved methods of evading or neutralizing the antibiotics 
which can be passed horizontally, by passing and receiving plasmids containing 
resistant genes, and then spread vertically to their daughter cells. Most clinically 
approved antibiotics target only a few pathways, such as folate, and cell wall 
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biosynthesis, as protein synthesis in the ribosome.19,22 Between selective pressure and 
horizontal gene transfer, bacteria can develop or acquire resistance to natural product 
antibiotics that attack these highly conserved bacterial pathways given time and 
exposure. It is more perplexing to consider the case of synthetic antibiotics such as 
fluoroquinolones, which are currently the only clinically approved antibiotics that attack 
DNA replication. Being entirely synthetic, one might expect that resistance to 
fluoroquinolones would be slower to develop due to a lack of ready-made defenses 
present in the bacterial genome, but bacteria are able to respond to fluoroquinolones 
through both adaptation of cellular responses as well as acquiring low level resistance 
mechanisms through co-opting other cellular response pathways. The qnr genes are an 
important example of how bacteria can respond to synthetic antibiotics. QnrA and qnrS, 
thought to originate from the marine algae Shewanella algae, aids bacterial replication 
by easing DNA relaxation ahead of the replication fork which also gives a protective 
effect against flouroquinolones.23 Plasmids carrying these genes are increasingly found 
in cases of low level fluoroquinolone resistant pathogens and it has been shown that 
they greatly increase the likelihood of developing high level resistance.  
An equally pressing question: why do the wild-type S. aureus display 
considerable resistance to the natural product DNM, which targets DNA replication, 
when the fluoroquinolone resistant strains possessing gyrase A mutations of S84L, as in 
the majority of MRSA cases, are highly susceptible?20,21 This same serine mutation is 
known across a number of FQR bacterial species and is consistently associated with 
resistance to the synthetic antibiotic fluoroquinolones.20 It has even been shown that 
cycling DNM and ciprofloxacin exposure can result in resistance and reversion of that 
5  
resistance back to wild type suggesting that the key difference between the two strains 
hinges on this serine.20 In other words, why is a natural product antibiotic like DNM 
mostly ineffective against wild-type bacteria, but highly potent against bacteria that have 
undergone this serine mutation to resist fluoroquinolones? 
 Though DNM has been shown to inhibit the mutant DNA gyrase A, the exact 
nature of its complex with bacterial DNA and proteins remains unknown as no crystal 
structure has been reported. It is, however, believed that the presence of this serine 84 
allows for fluoroquinolones to function by helping forming a Mn2+ water bridging 
interaction between the keto acid motif of fluoroquinolones and the serine, thus 
stabilizing the cleavage complex and giving fluoroquinolones their potency (Figure 
1.2).24,25 Based upon DNM’s lack of strong potency against bacteria possessing this 
serine, and its status as a natural product, it is possible that the large degree of 
conservation of the serine across many bacterial species is itself a resistance 
mechanism against DNM and NM which the fluoroquinolones such as ciprofloxacin are 
exploiting for their mode of action. The mutation of the serine to a leucine or isoleucine, 
which has been shown to be achievable with a single point mutation, is then a reversion 
or a mutation along a previous pathway to avoid the fully synthetic fluoroquinolones.  
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Figure 1.2 Keto-acid motif of fluoroquinolones chelates a Mn2+ ion (pink circle) forming 
a water (blue circles) bridge to the serine residue in Gyr A of B. anthracis. Mutation of 
Ser81 disrupts this interaction. Figure adapted from Wohlkonig et al.26 
 
1.4 Summary 
Antibiotic resistance is a recognized and still growing problem of immense clinical 
relevance. The need to discover and develop new antibiotics is obvious, and the DNM 
platform demonstrates a method of subverting the usual bacterial resistance 
mechanisms to target FQR bacteria. Because it targets the mutation that confers 
resistance to the synthetic fluoroquinolones, resistance to DNM typically restores 
susceptibility to fluoroquinolones thus preventing the generation of new more highly 
resistant bacterial strains. The difficulty in accessing DNM derivatives synthetically and 
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its lack of potency against the fluoroquinolone sensitive S. aureus, as well as against 
gram negative pathogens has largely inhibited its exploration as an antibiotic. 
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Chapter 2. Synthesizing Deoxynybomycin derivatives for activity against FQR 
gram positive and gram negative pathogens 
Portions of this chapter are reprinted with permission form Parkinson, E. I.; Bair, J. S.; 
Nakamura, B.; Lee, H. Y.; Kuttab, H. I.; Southgate, E. H.; Lezmi, S. Lau, G. W.; 
Hergenrother, P. J. Nat. Commun. 2015, 6, 6947. Copyright 2015 Nature Publishing 
Group. Contributions of others are noted when applicable. 
2.1 Previous advances in deoxynybomycin synthesis 
When DNM was reported to possess activity against FQR S. aureus as well as 
M. smegmatis and Bacillus species there was still no practical synthetic route to 
produce significant quantities and new derivatives of DNM.1 Efforts by Dr. Elizabeth 
Parkinson, a previous graduate student in the Hergenrother group,  resulted in a 
modular synthetic route that allowed access to several DNM derivatives with simple 
alkyl substitutions at four positions on the core scaffold by using a late stage 
intermediate in a previously developed synthesis of deoxynyboquinone by Dr. Joseph 
Bair.2 Fourteen derivatives of DNM were synthesized in 7 steps with an 11% overall 
yield. 
2.1.1 Goals in synthesizing new DNM derivatives 
Despite many of these compounds showing increased solubility (3-13 fold in pH 
7.4 buffered saline compared to the parent DNM) with comparable potency against FQR 
S. aureus,2 it was thought that solubility and by extension pharmacokinetic properties 
could be improved further with the synthesis of DNM derivatives containing polar 
functionality. It was hypothesized that the synthetic route could be modified to carry 
protected functional groups, to be unmasked as the desired derivatives. Additionally, we 
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hypothesized that some polar derivatives could display greater efficacy against FQR 
bacteria expressing alternative serine mutations to polar residues such as arginine, 
against which DNM has reduced potency. Eventually it became clear that further 
functionalization at the methylene bridge of the five member ring (site D in Figure 2.1) 
could allow access to further derivatives with increases in solubility, and this became a 
new site of derivatization.  
 
      
 
 
 
Figure 2.1 Structure of deoxnybomycin, with primary sites of derivatization labeled A-D. 
 
2.2 Synthesis of nybomycin and DNM derivatives containing polar functionality 
 Building on work previously performed in the Hergenrother research group, 
several DNM derivatives were synthesized by making modifications to the previous 
route to carry methyl protected alcohols which would then be unmasked and 
transformed into the desired functional groups (Figure 2.2).2 The route involved the 
synthesis of two vinyl iodo-amide cross coupling partners carrying the derivatives’ 
modifications, and their use in a mixed Suzuki cross coupling with a symmetrical aryl 
boronate. The mixed cross coupling produced both symmetrically and non 
symmetrically substituted products, and the desired cross coupling product was 
isolated. Subsequently, a palladium-catalyzed Buchwald-Hartwig ring closing was used 
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to generate the diazanthracene which was then unmasked via HBr to reveal the 
dianthracenol. A methylene bridge was then inserted with dibromomethane to give the 
final DNM derivatives as previously described by Hergenrother and coworkers (Scheme 
2.1).2,3 
 This route was followed closely, but modified by the addition of protected 
functional groups which could be carried inert through the route and deprotected at the 
end to yield both a polar final product as well as a functional handle which could then be 
used to access new polar functionality. Nybomycin, as well as its amine variant (1, see 
Figure 2.2) were selected as targets as nybomycin could be compared to literature 
values, and 2 and 3 were selected do to their similarities to a DNM variant 4 possessing 
an alkyl chain whose activity was known to be comparable to DNM.2 
   
 
 
 
 
 
 
Figure 2.2 Targets for synthesis containing polar functionality. DNM-8, 4 originally 
synthesized by Dr. Elizabeth Parkinson. 
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2.2.1 Proposed route for synthesis of DNM derivatives with polar functionality 
 Adapting the previous synthesis it was hypothesized that protected functional 
groups could be carried through the synthetic route to be unmasked following 
diazanthracene formation (Scheme 2.1). Full experimental details including tabulated 
spectra can be found in section 2.5. 
 
Scheme 2.1 Proposed synthesis of NM and 1 via adaptation of DNM synthetic route 
using cross coupling partners with protected polar functional groups. 
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A number of protecting groups were utilized in an attempt to carry polar 
functionality through the route. As the route hinged on a Pd-mediated Suzuki cross 
coupling carried out in the presence of base and water it was necessary to use 
functional groups that were stable to basic and aqueous conditions. Most challenging, 
the protecting group or the polar functionality it masked would have to be stable through 
the harsh 48% HBr or BBr3 as a result of the need to deprotect the aryl methyl ether. 
Finally, protecting groups carrying polar functionality to the A or B position (see Figure 
2.1) would need to be stable to n-BuLi as well as refluxing acetic acid used during the 
synthesis of the iodoamide coupling partners. 
2.2.2 Synthesizing cross coupling partners with masked polar functional groups  
To optimize step economy, both primary amines and alcohols were intended to 
serve as starting materials for the synthesis of the iodoamide coupling partners. As it 
was expected that the amine would need to be completely protected for the addition of 
ethyl chloroformate, a pthallamide protecting group was chosen due its relative stability 
and the ability to deprotect it orthogonally later on. 17 was formed in near quantitative 
yield through the reaction of commercially available 16 with potassium pthalimide. 
Ultimately this line of inquiry was abandoned due to immediate polymerization upon 
exposing the pthalimide protected amine to n-BuLi at any concentration or temperature 
(Scheme 2.2). 
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Scheme 2.2 Attempts to carry a primary amine with a protecting group as a 
trisubstituted amine were unsuccessful as polymerization stymies attempts to make 16. 
 
After the primary amine showed difficulties in achieving the intended results, a 
primary alcohol was chosen as the protected functionality to carry through the synthetic 
route as it could be easily installed, masked, and starting materials containing them 
were cheap and abundant. 19 was chosen as a starting point due to its commercial 
availability, and 20 was synthesized via reaction with dimethyl sulfate. The methyl 
protected propargyl ether was deprotonated with n-BuLi and reacted with ethyl 
chloroformate to generate the protected ester 21. Amide 22 was synthesized from 21 
through the addition of 2M methylamine. 23 was synthesized from 22 through refluxing 
acetic acid in the presence of NaI (Scheme 2.3).2 Cross coupling partner 26 was 
synthesized from commercially available 24 by analogous reactions with 
methoxyethylamine and sodium iodide. See section 2.4 for full synthetic protocols. 
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Scheme 2.3 Synthesis of methyl protected iodoamides 23 and 26 for use as coupling 
partners 
 
2.2.3 Synthesizing polar DNM derivatives from cross coupling partners 
 After obtaining cross coupling partners 23 and 26, a mixed cross coupling was 
carried out according to the previously established protocols with symmetrical aryl 
boronate 11 and 10 resulting in 27 and 29 in 30-38% yields as well as small amounts of 
the symmetrically coupled products (Scheme 2.4).3 The compounds were subjected to 
the palladium catalyzed ring closing reaction to give 28 and 30 in over 90% yields. 
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Scheme 2.4 Dianthracenes 28 and 30 synthesized from mixed cross couplings followed 
by palladium mediated ring closing. 
 
 Based upon Rineheart et al’s synthesis of deoxnybomycin it was hypothesized 
that the use of HBr could result in the loss of the alcohol along with its methyl protecting 
group.4,5 A two-step deprotection strategy was thus employed in which TFA was first 
used to deprotect the PMB group which resulted in 31 and 32. Several agents were 
then used to attempt a selective demethylation of the phenol or methyl protected alkyl 
ether (Scheme 2.5).3 Despite proving successful in the demethylation of simple anisole, 
neither thiol lithium salts nor aluminum and triiodide were able to deprotect either 
alcohol.6,7 Ultimately BBr3 was used to deprotect at both positions simultaneously 
resulting in the fully deprotected dianthracenes 34 and 35 (Scheme 2.5). 
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Scheme 2.5 Fully deprotected dianthracenes 34 and 35 synthesized from TFA and 
BBr3.  
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With the alcohols now unmasked, the resultant dianthracenes were insoluble in 
most organic solvents except for DMF. The products could not be readily purified by 
chromatography. Furthermore, attempts to insert the methylene bridge resulted in non-
selective alkylation that thwarted attempts to produce the polar products in good yields, 
though NM was prepared from 34 in very low yields (Scheme 2.6).  
 
  
 
 
Scheme 2.6 Nybomycin synthesized in low yields from 34. 
 
Instead of attempting the bridge insertion and then transforming the alcohols to 
the desired amines, the alcohols were first tosylated to produce 36 and 38, then 
displaced by excess sodium azide to generate 37 and 39 (Scheme 2.7). The Mitsunobu 
reaction was also successful in generating the azides 37 and 39, but it also produced 
inseparable phosphine oxide contamination that ultimately rendered it unusable.  
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Scheme 2.7 Azides 37 and 39 generated from tosylation and displacement of primary 
alcohols 34 and 35. 
 
Finally, the methylene bridge could be inserted by dibromomethane addition to 
37 and 39 to synthesize 40 and 41 which were much more soluble in organic 
compounds and comparatively easier to isolate (Scheme 2.8). Azides 40 and 41 were 
reduced to their amines 1 and 3 by Lindlar’s catalyst with 1 atm hydrogen to avoid any 
issues with reducing the core ring system. In this manner, amines 1 and 3 were 
synthesized in 12 steps and 0.63% yield for 1 and 9 steps and 0.3% yield for 3. 
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Scheme 2.8 Amines 1 and 3 were synthesized by reduction with Lindlar’s catalyst. 
 
Section 2.3 Synthesis of new DNM derivatives off the five-membered ring 
 Though positions 1-3 had been investigated with a variety of alkyl substitutions 
and position 4 has seen the addition of a methyl group, there were still opportunities to 
further the SAR at the five member ring (figure 2.1).2 In order to investigate the effects 
of substitution at that position on antibacterial activity, three new derivatives were 
synthesized as simple variations on a 6 member ring from 44 and 46 whose synthesis 
was previously reported by the Hergenrother group.2 Following the usual bridge 
insertion protocol, alkyl bromides were used to extend the five-membered ring. 
Additionally, derivative 49 containing a phenyl ring was synthesized using benzaldehyde 
to examine whether substitutions of this size and shape would be tolerated (Scheme 
2.9). 
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Scheme 2.9 DNM derivatives from the five membered ring core were synthesized. 
 
Section 2.4 Evaluating new derivatives for antibiotic activity against wild type and 
FQR S. aureus 
 The DNM derivatives newly synthesized above were tested for activity against 
wild type (ATCC 29213) and FQR (NRS3) S. aureus using 3 repetitions of the standard 
microbroth dilution assay to determine MIC (Figure 2.3). These two strains display the 
critical S84 and S84L residues that confer fluoroquinolone resistance and DNM 
sensitivity (see chapter 1). The activity of several DNM derivatives has already been 
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reported against these strains.2 The susceptibility of 29213 and NRS3 was determined 
for the newly synthesized derivatives (table 2.1).  
All of the derivatives made off the five-membered ring maintained both their 
strong selectivity for the FQR strain (448 is 246 times more potent against FQR S. 
aureus) as well as their general efficacy with the exception of 49. The lack of potency 
suggested that the steric bulk of the phenyl ring of 49 may be too large, and it may be 
inhibiting the usual mode of binding. In contrast, 4, 45, 47 and 48 all retained potency 
just short of the parent compound DNM, while being soluble in this assay at higher 
concentrations in DMSO. 
The polar derivatives including amines 1 and 3 as well as azides 40 and 41 were 
unfortunately much less potent against FQR S. aureus though at least one maintained a 
strong (16fold) preference for the FQR strain which suggested an engagement with its 
target. All derivatives were soluble at concentrations of at least 0.8 mg/mL in DMSO.  
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Figure 2.3 Newly synthesized DNM derivatives including amines and derivations from 
the five-membered ring 
  
Table 2.1 Sensitivity of wild type and fluoroquinolone resistant S. aureus with 
DNM, CIP, and DNM derivatives 
Strain DNM MIC μg/mL 
CIP MIC μg/mL 
45 MIC μg/mL 
47 MIC μg/mL 
48 MIC μg/mL 
49 MIC μg/mL 
40 MIC μg/mL 
1 MIC μg/mL 
41 MIC μg/mL 
3 MIC μg/mL 
29213 >1 0.5 4 16 16 >64 16 32 32 16 
NRS3 0.03 >64 0.062 0.125 0.062 >64 8 16 32 1 
MIC’s determined against fluoroquinolone sensitive (29213) and FWR (NRS3) S. 
aureus strains by microdilution broth method (see Section 2.6). 40, 1, 41, and 3 were 
tested by Dr. Elizabeth Parkinson. 
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Section 2.5 Chemistry materials and methods 
 General chemical reagents were purchased from Sigma Aldrich and used without 
further purification except where indicated. Palladium catalysts and ligands were 
purchased from Strem Chemicals Inc. (Newburyport, MA). Ethyl 2-butynoate was 
purchased from GFS Chemicals (Powell, OH) and bis-pinacolboronate was purchased 
from Frontier Scientific (Logan, UT). In some cases vinyl iodoamide 10 and aryl 
boronate 11 were obtained from Wu Xi. Solvents were dried by passage through 
columns packed with activated alumina (THF, CH2Cl2, diethyl ether) or activated 
molecular sieves (DMSO). Reactions involving n-BuLi or LDA were performed using 
standard Schlenk techniques under argon.  
 1H-NMR and 13C spectra were recorded on Varian Unity spectrometers at 500 
MHz and 125MHz respectively. Spectra generated from a solution of CDCl3 were 
referenced to residual chloroform (1H: δ 7.26 ppm, 13C: δ 77.16 ppm). Spectra 
generated in mixtures of CDCl3 and CD3OD were referenced to CD3OD (1H: δ 3.31 
ppm, 13C: δ 49.0 ppm). 
Section 2.5.1 Synthetic protocols and characterizations 
 
To an oven dried flask with stir bar charged with 16 (0.93g, 5mmol) under argon 
was added 5mL dry DMF by syringe. Propargyl bromide was added (0.72 mL, 6.4mmol) 
and the mixture was heated to 80oC in an oil bath. The reaction was quenched two 
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hours later with the addition of DI water cooled in an ice bath resulting in a white 
precipitate that was isolated by filtration and dried under vacuum. The remaining 
solution was extracted twice with 10mL EtOAc and dried with MgSO4 before being 
filtered and dried under vacuum. Product 17 was a pure white solid obtained in 97% 
yield. 
1H NMR (500 MHz, CDCl3): δ 7.89 (dd, J = 1.0 Hz, 2H), 7.74 (d, J = 1.0 Hz, 2H), 4.46 
(d, J=1Hz, 2H), 2.23 (t, J= 1Hz, 1H)  
13C NMR (125 MHz, CDCl3): δ 168.2, 132.1, 131, 123.8, 78, 73.2, 30.5  
 
 To a flask with stir bar was added 19 (3.5mL, 59.2mmol) and 50% NaOH 
(4.33mL). The solution was cooled to 0oC on ice and then dimethyl sulfate (3.36mL, 
35.12mmol) was added. The solution was prevented from reaching 50oC, and stirred for 
14 hours. The solution was then distilled, giving the product at 81oC as a clear oil with 
73% yield. 
1H NMR (500 MHz, CDCl3): δ 4.1 (d, J = 1.0 Hz, 2H), 3.39 (s, 3H), 2.44 (t, J=1Hz, 1H) 
13C NMR (125 MHz, CDCl3): δ 78.7, 76.4, 59.6, 58.1  
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To an oven dried flask containing a magnetic stir bar and flushed with argon was 
added recently distilled 20 (0.5mL, 5.92mmol) and THF (6mL). The solution was cooled 
using a dry ice IPA bath, and n-BuLi was added dropwise (4.1mL, 6.52mmol). After 30 
minutes, ethyl chloroformate was added dropwise (0.7mL, 7.3mmol) and the solution 
was allowed to stir overnight gradually warming to 0oC. After 15 hours water was added 
and the mixture was extracted with ethyl acetate 5mL three times. The ethyl acetate 
was brined, dried under MgSO4 and evaporated under reduced pressure down to an oil. 
The oil was purified by column chromatography using 9:1 hexanes to ethyl acetate with 
an Rf of 0.2. The product was a clear oil obtained in 84% yield. 
1H NMR (500 MHz, CDCl3): δ 4.24 (q, J = 7.0 Hz, 2H), 4.22 (s, 2H), 3.41 (s, 3H), 1.31 (t, 
J=7Hz, 3H) 
13C NMR (125 MHz, CDCl3): δ 161.2, 89.3, 82, 62.1, 59.7, 58.1, 13.2 
 
 To a 7mL vial with stirbar containing 21 (2g, 14mmol) was added methanol 
(5.55mL) and the solution was cooled in an ice water bath. The amine was added 
(8.4mL), and the solution was stirred overnight. The solution was evaporated directly 
from the vial under reduced pressure after 10hr, and the residue was separated by silica 
gel chromatography (9:1 hexanes:ethyl acetate to 1:1 hexanes: ethyl acetate) to give 
the product as a clear oil in 69% yield. 
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1H NMR (500 MHz, CDCl3): δ 5.75 (bs, 1H, major rotomer NH), 5.56 (bs, 1H, minor 
rotomer NH), 4.22 (s, 2H), 3.41 (s, 3H), 2.98 (d, 3H, J=5Hz, minor rotomer NCH3) 
2.81(d, 3H, J=5Hz, major rotomer NCH3)  
13C NMR (125 MHz, CDCl3): δ 154.2 (minor), 153.6 (major), 89.3, 82, 61.8 (minor), 59.9 
(major), 59.7, 58.1 
 
Alkynyl amide 22, (1.01g, 7.9mmol), NaI (16mmol) and glacial acetic acid (1mL, 
17.5mmol) were combined in a 1dram vial. The vial was sealed and heated to 115oC for 
9hr. The deep red mixture was diluted with water (8mL) and CH2Cl2 (27mL) and treated 
with NaHSO3 until colorless. The mixture was then neutralized with NaHCO3. The 
mixture was partitioned and the aqueous layer was extracted with CH2Cl2 three times 
with 15mL. The combined organic fractions were brined, dried with MgSO4 and 
evaporated to yield the desired iodoamide 23 as a white-yellow solid in 82% yield. 
1H NMR (500 MHz, CDCl3): δ 6.67 (s, 1H, vinyl CH), 5.74 (bs, 1H), 4.13 (s, 2H), 3.4 (s, 
3H), 2.91 (d, J = 1.0 Hz, 3H) 
13C NMR (125 MHz, CDCl3): δ 166.2, 129.8, 104.5, 82.8, 59.2, 23.8 
 
To a 7mL vial with stirbar containing 24 (1g, 8.9mmol) was added methanol 
(8.9mL) and the solution was cooled in an ice water bath. The amine was added 
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(10.68mmol), and the solution was stirred overnight. The solution was evaporated 
directly from the vial under reduced pressure after 10hr, and the residue was separated 
by silica gel chromatography (9:1 hexanes:ethyl acetate to 1:1 hexanes: ethyl acetate) 
to give the product as a clear oil in 77% yield. 
1H NMR (500 MHz, CDCl3): δ 6.12 (bs, 1H, NH), 3.57 (m, 2H), 3.46 (m, 2H), 3.36 (s, 
3H), 1.94 (s, 3H)  
13C NMR (125 MHz, CDCl3): 145.2, 83.6, 75.03, 70.98, 59.03, 39.6, 3.91  
 
 
Alkynyl amide 25, (2.07g, 14.66mmol), NaI (29.3mmol) and glacial acetic acid 
(1.7mL, 29.75mmol) were combined in a 1dram vial. The vial was sealed and heated to 
115oC for 9hr. The deep red mixture was diluted with water (15mL) and CH2Cl2 (55mL) 
and treated with NaHSO3 until colorless. The mixture was then neutralized with 
NaHCO3. The mixture was partitioned and the aqueous layer was extracted with CH2Cl2 
three times with 30mL. The combined organic fractions were brined, dried with MgSO4 
and evaporated to yield the desired iodoamide 26 as a white solid in 70% yield. 
1H NMR (500 MHz, CDCl3): δ 7.3 (bs, 1H, NH), 7.1 (s, 1H), 3.51 (m, 2H), 3.38 (m, 2H), 
3.42 (s, 3H), 2.02 (s, 3H) 
13C NMR (125 MHz, CDCl3): δ 145.2, 130.5, 116.4, 71.6, 59.0, 39.6, 31.8  
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 To a flask with a stir bar was added 11 (1.4mmol), PdCl2(dppf) (20mol%, 
0.28mmol), K2CO3 (8.4mmol) and both desired iodoamides 23 (2.1mmol) and 10 
(1.82mmol). The flask was evacuated and backfilled three times with argon. Water 
(3mL) and DME (27mL) were degassed by sparging 45 minutes with argon and added 
by syringe. The flask was plunged into an oil bath at 80oC for 3.5hr. The mixture was 
poured into a seperatory funnel and diluted with water (15mL). The mixture was 
partitioned and the aqueous layer was extracted with EtOAc (3x 30mL). The organic 
fractions were combined, washed with brine, and evaporated to a red foamy solid. The 
crude solid was dissolved in approximately 3mL CH2Cl2 and sepereated by silica gel 
chromatography (100:0 to 70:30 to 30:700 to 0:100 hexanes:ethyl acetate). The purity 
of the resultant product was variable and was subjected to the intramolecular amidation 
without further purification but 38% presents a typical yield of an off white foam. 
1H NMR (500 MHz, CDCl3): δ 7.1 (s, 1H, anisole CH), 7.01 (d, 2H, J=8.5Hz, PMB CH), 
6.62 (d, 2H, J=8.5Hz, PMB CH), 6.35 (bs, 1H, NH), 6.3 (bs, 1H, NH), 5.89 (s, 1H, vinyl 
CH), 5.63 (s, 1H, vinyl CH), 5.3 (bd, 2H, benzyl CH2), 4.42 (s, 2H), 3.72 (s, 3H), 3.68 (s, 
3H), 3.65 (s, 3H), 2.46 (d, 3H, J=1.0Hz)  
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 In a schlenk flask the diamide starting material 27 (0.6mmol) was combined with 
K2CO3 (3.6mmol), Pd/X-phos admix (10mol%) and argon sparged isopropanol (20mL). 
The mixture was heated to 100oC and monitored by NMR of aliquots. Insoluble 
materials were removed by filtration through celite and rinsed with CH2Cl2. The filtrate 
was evaporated to give 28 as a white foam or solid. The product varied in purity but was 
typically used without further purification. 
1H NMR (500 MHz, CDCl3): δ 7.72 (s, 1H, anisole CH), 7.09 (d, 2H, J=8.5Hz, PMB CH), 
6.73 (d, 2H, J=8.5Hz, PMB CH), 6.78 (s, 1H, vinyl CH), 6.52 (d, 1H, J=1.0Hz, vinyl CH), 
5.3 (bd, 2H, benzyl CH2), 4.42 (s, 2H), 3.72 (s, 3H), 3.68 (s, 3H), 3.65 (s, 3H), 2.46 (d, 
3H, J=1.0Hz)  
13C NMR (125 MHz, CDCl3): 164.86, 164.84, 147.6, 146.2, 137.0, 136.8, 129.8, 128.5, 
120.3, 120.27, 120.2, 119.1, 113.6, 71.16, 62.5, 58.81, 55.3, 36.3, 20.04 
 
To a flask with a stir bar was added 11 (1.4mmol), PdCl2(dppf) (20mol%, 
0.28mmol), K2CO3 (8.4mmol) and both desired iodoamides 26 (2.1mmol) and 10 
(1.82mmol). The flask was evacuated and backfilled three times with argon. Water 
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(3mL) and DME (27mL) were degassed by sparging 45 minutes with argon and added 
by syringe. The flask was plunged into an oil bath at 80oC for 3.5hr. The mixture was 
poured into a seperatory funnel and diluted with water (15mL). The mixture was 
partitioned and the aqueous layer was extracted with EtOAc (3x 30mL). The organic 
fractions were combined, washed with brine, and evaporated to a red foamy solid. The 
crude solid was dissolved in approximately 3mL CH2Cl2 and separated by silica gel 
chromatography (100:0 to 70:30 to 30:700 to 0:100 hexanes:ethylacetate). The purity of 
the resultant product was variable and was subjected to the intramolecular amidation 
without further purification but 30% presents a typical yield.  
1H NMR (500 MHz, CDCl3): δ 7.1 (s, 1H, anisole CH), 7.01 (d, 2H, J=8.5Hz, PMB CH), 
6.62 (d, 2H, J=8.5Hz, PMB CH), 6.35 (bs, 1H, NH), 6.3 (bs, 1H, NH), 5.99 (d, 1H, 
J=1Hz, vinyl CH), 5.91 (d, 1H, J=1Hz, vinyl CH), 5.3 (bd, 2H, benzyl CH2), 3.68 (s, 3H), 
3.62 (m, 2H), 3.48 (s, 3H), 3.40 (m, 2H), 2.65 (d, 3H J=1Hz), 2.46 (d, 3H, J=1.0Hz)  
 
In a schlenk flask the diamide starting material 29 (0.4mmol) was combined with 
K2CO3 (2.4mmol), Pd/X-phos admix (10mol%) and argon sparged isopropanol (10mL). 
The mixture was heated to 100oC and monitored by NMR of aliquots. Insoluble 
materials were removed by filtration through celite and rinsed with CH2Cl2. The filtrate 
was evaporated to give 30 as a white foam or solid. The product varied in purity but was 
typically used without further purification. 
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1H NMR (500 MHz, CDCl3): δ 7.6 (s, 1H, anisole CH), 7.01 (d, 2H, J=8.5Hz, PMB CH), 
6.62 (d, 2H, J=8.5Hz, PMB CH), 6.52 (d, 1H, J=1Hz, vinyl CH), 6.39 (d, 1H, J=1Hz, vinyl 
CH), 5.3 (bd, 2H, benzyl CH2), 3.68 (s, 3H), 3.62 (m, 2H), 3.48 (s, 3H), 3.40 (m, 2H), 
2.65 (d, 3H J=1Hz), 2.46 (d, 3H, J=1.0Hz) 
13C NMR (125 MHz, CDCl3): δ 162.3, 159.87, 146.3, 145.8, 137.7, 136.43, 128.8, 127.2, 
120.9, 120.16, 120.11, 119.1, 113.6, 71.16, 70.8, 62.5, 59.6, 55.3, 43.2, 20.04 
NNO OO
O
PMB
28
TFAreflux95% NHNO OO
O
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 28 was evaporated into a flask (0.2mmol). TFA was added (3mL) and the 
solution was heated to reflux for 1.5 hours. The solvent was evaporated and the residue 
was purified by silica gel chromatography to give 31 as an off white solid in 95% yield. 
1H NMR (500 MHz, CDCl3): δ 7.73 (s, 1H), 6.62 (s, 1H, vinyl CH), 6.41 (s, 1H, vinyl CH), 
4.6 (s, 2H), 3.85 (s, 3H), 3.39 (s, 3H), 2.44 (s, 3H)  
 
30 was evaporated into a flask (0.2mmol). TFA was added (3mL) and the 
solution was heated to reflux for 1.5 hours. The solvent was evaporated and the residue 
was purified by silica gel chromatography to give 32 as an off white solid in 93% yield. 
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1H NMR (500 MHz, CDCl3): δ 7.69 (s, 1H), 6.52 (d, 1H, J=1Hz, vinyl CH), 6.39 (d, 1H, 
J=1Hz, vinyl CH), 3.68 (s, 3H), 3.62 (m, 2H), 3.40 (m, 2H), 2.65 (d, 3H J=1Hz), 2.46 (d, 
3H, J=1.0Hz) 
 
 31 (20mg 0.06mmol) was charged into a dried flask with a magnetic stirrer under 
argon. Dried DCM (1mL) was added by syringe. The solution was chilled with a dry ice 
IPA bath, and BBr3 (0.636mmol) was added dropwise. The solution was allowed to stir 
for 4 hours and monitored by TLC until starting material was consumed. The reaction 
was neutralized with concentrated NaHCO3, and the solvents were evaporated to give 
the product 34 as a brown-red solid. The solid was not completely pure, but purity was 
increased by washing with hexanes and 34 used without further purification. 
1H NMR (500 MHz, CDCl3): δ 7.81 (s, 1H), 6.68 (s, 1H, vinyl CH), 6.41 (s, 1H, vinyl CH), 
4.4 (s, 2H), 3.12 (s, 3H) 2.44 (s, 3H) 
 
34 (110mg, 0.384mmol) was placed in a flask with 20mL DCM, and Et3N was 
added (1.152mmol). Tosyl chloride was added by portion (90mg, 0.46mmol) and the 
solution was heated while stirring to 75oC in an oil bath. Reaction was monitored by 
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TLC and after the starting material was consumed the solvents were evaporated. After 
thoroughly removing all DCM, DMF was added with NaN3 (1.19mmol), and the reaction 
was allowed to stir at 65 degrees overnight. Water was added to quench the reaction 
and the solvents were evaporated to give 37 impure as a black solid. 
1H NMR (500 MHz, CDCl3): δ 7.81 (s, 1H), 6.68 (s, 1H, vinyl CH), 6.41 (s, 1H, vinyl CH), 
3.9 (s, 2H), 3.12 (s, 3H) 2.44 (s, 3H) 
HRMS (m/z, ESI-TOF): (M+H)+ calcd for C15H13N5O3, 311.1709; found, 311.1714. 
 
30 (20mg 0.06mmol) was charged into a dried flask with a magnetic stirrer under 
argon. Dried DCM (1.5mL) was added by syringe. The solution was chilled with a dry 
ice IPA bath, and BBr3 (0.65mmol) was added dropwise. The solution was allowed to 
stir for 4 hours and monitored by TLC until starting material was consumed. The 
reaction was neutralized with concentrated NaHCO3, and the solvents were evaporated 
to give the product 35 as a brown-red solid. The solid was not completely pure, but 
purity was increased by washing with hexanes and 35 used without further purification. 
1H NMR (500 MHz, CDCl3): δ 7.71 (s, 1H), 6.52 (d, 1H, J=1Hz, vinyl CH), 6.39 (d, 1H, 
J=1Hz, vinyl CH), 3.59 (m, 2H), 3.32 (m, 2H), 2.58 (d, 3H J=1Hz), 2.46 (d, 3H, J=1.0Hz) 
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35 (65 mg, 0.225mmol) was placed in a flask with 10mL DCM, and Et3N was 
added (0.68mmol). Tosyl chloride was added by portion (50mg, 0.27mmol) and the 
solution was heated while stirring to 75oC in an oil bath. Reaction was monitored by 
TLC and after the starting material was consumed the solvents were evaporated. After 
thoroughly removing all DCM, DMF was added with NaN3 (0.681mmol), and the 
reaction was allowed to stir at 65 degrees overnight. Water was added to quench the 
reaction and the solvents were evaporated to give 39 impure as a black solid. 
1H NMR (500 MHz, CDCl3): δ 7.71 (s, 1H), 6.52 (d, 1H, J=1Hz, vinyl CH), 6.39 (d, 1H, 
J=1Hz, vinyl CH), 3.16 (m, 2H), 3.1 (m, 2H), 2.58 (d, 3H J=1Hz), 2.46 (d, 3H, J=1.0Hz) 
HRMS (m/z, ESI-TOF): (M+H)+ calcd for C16H15N5O3, 325.122; found, 325.1227. 
 
 
In a flask containing a magnetic stir bar 37 (8mg) was combined with K2CO3 
(21mg) and dissolved in DMF (2mL). CH2Br2 (1mL) was added and the solution was 
heated to 95oC for 5hr and monitored by TLC (10%MeOH in EtOAc) for the 
disappearance of starting material. DMF was evaporated, and the residue was 
dissolved in EtOAc and methanol and filtered. The residue was evaporated to a brown 
solid, and isolated by silica gel chromatography (8%MeOH in EtoAc) to give 40 as an off 
white solid in 16% yield. 
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1H NMR (500 MHz, CDCl3): δ 7.81 (s, 1H), 6.68 (s, 1H, vinyl CH), 6.41 (s, 1H, vinyl CH), 
6.38 (s, 2H), 3.9 (s, 2H), 3.12 (s, 3H) 2.44 (s, 3H) 
HRMS (m/z, ESI-TOF): (M+H)+ calcd for C16H13N5O3, 323.8965; found, 323.8974. 
 
 40 was placed in a 7mL vial along with 1mol% Lindlar’s catalyst and 1mL 
methanol under an atmosphere of Hydrogen. The reaction was allowed to stir at room 
temperature for 4 hours. More methanol was added, and the solution was filtered. The 
solution was evaporated under reduced pressure and purified by silica gel 
chromatography with 5% MeOH in DCM to give 1 as a tan solid. 
1H NMR (500 MHz, CDCl3): δ 7.81 (s, 1H), 6.68 (s, 1H, vinyl CH), 6.41 (s, 1H, vinyl CH), 
6.38 (s, 2H), 3.86 (m, 2H), 3.12 (s, 3H) 2.44 (s, 3H), 2.1 (bs, 2H) 
HRMS (m/z, ESI-TOF): (M+H)+ calcd for C16H15N3O3, 297.1175; found, 297.1179. 
 
In a flask containing a magnetic stir bar 39 (4mg) was combined with K2CO3 
(12mg) and dissolved in DMF (1mL). CH2Br2 (0.5mL) was added and the solution was 
heated to 95oC for 5hr and monitored by TLC (10%MeOH in EtOAc) for the 
disappearance of starting material. DMF was evaporated, and the residue was 
dissolved in EtOAc and methanol and filtered. The residue was evaporated to a brown 
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solid, and isolated by silica gel chromatography (8%MeOH in EtoAc) to give 42 as an off 
white solid in 14% yield. 
1H NMR (500 MHz, CDCl3): δ 7.71 (s, 1H), 6.52 (d, 1H, J=1Hz, vinyl CH), 6.39 (d, 1H, 
J=1Hz, vinyl CH), 6.24 (s, 2H) 3.16 (m, 2H), 3.1 (m, 2H), 2.58 (d, 3H J=1Hz), 2.46 (d, 
3H, J=1.0Hz) 
HRMS (m/z, ESI-TOF): (M+H)+ calcd for C17H15N5O3, 337.1208; found, 337.1209. 
 
42 was placed in a 7mL vial along with 1mol% Lindlar’s catalyst and 1mL 
methanol under an atmosphere of Hydrogen. The reaction was allowed to stir at room 
temperature for 4 hours. More methanol was added, and the solution was filtered. The 
solution was evaporated under reduced pressure and purified by silica gel 
chromatography with 5% MeOH in DCM to give 3 as a gray/offwhite powder. 
1H NMR (500 MHz, CDCl3): δ 7.71 (s, 1H), 6.52 (d, 1H, J=1Hz, vinyl CH), 6.39 (d, 1H, 
J=1Hz, vinyl CH), 6.24 (s, 2H) 3.16 (m, 2H), 3.1 (m, 2H), 2.58 (d, 3H J=1Hz), 2.46 (d, 
3H, J=1.0Hz), 2.05 (bs, 2H) 
HRMS (m/z, ESI-TOF): (M+H)+ calcd for C17H17N3O3, 311.1307; found, 339.1309. 
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In a flask containing a magnetic stir bar 44 (10mg) was combined with K2CO3 
(30mg) and dissolved in DMF (2mL). 1,2-Dibromoethane (1mL) was added and the 
solution was heated to 95oC for 5hr and monitored by TLC (10%MeOH in EtOAc) for the 
disappearance of starting material. DMF was evaporated, and the residue was 
dissolved in EtOAc and methanol and filtered. The residue was evaporated to a brown 
solid, and isolated by silica gel chromatography (8%MeOH in EtoAc) to give 45 as an off 
white solid in 36% yield. 
1H NMR (500 MHz, CDCl3): δ 7.55 (s, 1H), 6.49 (d, J = 1.0 Hz, 1H), 6.47 (d, J = 1.0 Hz, 
1H), 4.86 (d, J=1Hz, 2H), 4.39 (d, J=1Hz, 2H), 3.92 (s, 3H), 2.54 (d, J = 1.0 Hz, 3H), 
2.52 (d, J = 1.0 Hz, 3H); 
 
In a flask containing a magnetic stir bar 46 (10mg) was combined with K2CO3 
(30mg) and dissolved in DMF (2mL). 1,2-Dibromoethane (1mL) was added and the 
solution was heated to 95oC for 5hr and monitored by TLC (10%MeOH in EtOAc) for the 
disappearance of starting material. DMF was evaporated, and the residue was 
dissolved in EtOAc and methanol and filtered. The residue was evaporated to a tan 
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solid, and isolated by silica gel chromatography (8%MeOH in EtoAc) to give 47 as an off 
white solid in 37% yield. 
1H NMR (500 MHz, CDCl3): δ 7.55 (s, 1H), 6.49 (d, J = 1.0 Hz, 1H), 6.47 (d, J = 1.0 Hz, 
1H), 4.86 (d, J=1Hz, 2H), 4.39 (d, J=1Hz, 2H), 3.99 (d, 2H, J=7Hz), 2.54 (d, J = 1.0 Hz, 
3H), 2.52 (d, J = 1.0 Hz, 3H); 1.36 (t, 3H, J=7Hz) 
 
 
In a flask containing a magnetic stir bar 44 (10mg) was combined with K2CO3 
(30mg) and dissolved in DMF (2mL). 1,2-Dibromopropane (1mL) was added and the 
solution was heated to 95oC for 5hr and monitored by TLC (10%MeOH in EtOAc) for the 
disappearance of starting material. DMF was evaporated, and the residue was 
dissolved in EtOAc and methanol and filtered. The residue was evaporated to a brown 
solid, and isolated by silica gel chromatography (8%MeOH in EtoAc) to give the 
products labeled 48 as a mixture of regioisomers and stereoisomers. Products could not 
be separated. 
1H NMR (500 MHz, CDCl3): δ 7.55 (s, 1H), 6.49 (d, J = 1.0 Hz, 1H), 6.47 (d, J = 1.0 Hz, 
1H), 4.91 (m, 1H major isomer), 4.86(m, 1H minor isomer) 4.43, (m, 1H major isomer) 
4.39 (m, 1H minor isomer), 3.92 (s, 3H), 2.54 (d, J = 1.0 Hz, 3H), 2.52 (d, J = 1.0 Hz, 
3H); 
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In a flask containing a magnetic stir bar 44 (20mg) was combined with K2CO3 
(30mg) and dissolved in DMF (4mL). Benzaldehyde (60mg) was added and the solution 
was heated to 90oC for 8hr and monitored by TLC (10%MeOH in EtOAc) for the 
disappearance of starting material. DMF was evaporated, and the residue was 
dissolved in EtOAc and methanol and filtered. The residue was evaporated to a brown 
solid, and isolated by silica gel chromatography (8%MeOH in EtoAc) to give 49 as an off 
white solid in 7% yield. 
1H NMR (500 MHz, CDCl3): δ 7.55 (s, 1H), 7.27 (d, 2H, J=7Hz), 7.25 (m, 2H), 7.19 (d, 
1H), 7.07 (s, 1H6.49 (d, J = 1.0 Hz, 1H), 6.47 (d, J = 1.0 Hz, 1H), 3.92 (s, 3H), 2.54 (d,  
J = 1.0 Hz, 3H), 2.52 (d, J = 1.0 Hz, 3H) 
Section 2.6 Antibiotic susceptibility tests 
 Antibiotic susceptibility for all bacterial strains was performed in triplicate using 
the microdilution broth method as outlined by the Clinical and Laboratory Standards 
Institute.8 MH broth was used. 2μL of a 50X compound stock in DMSO or water was 
added to the wells of a 96-well round well plate. Live and dead controls received 2μL of 
vehicle. 88μL of MH broth were added to the wells except the dead controls which 
received 98μL. 100μL of an overnight culture of bacteria were then added to 10mL of 
MH broth and grown until the inoculates reached a turbidity between 1*107 and 2*108 
cfu/mL based on a previously established calibration curve. The culture was diluted to 
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5*106 cfu/mL and 10μL of this solution was added to all but the dead control wells to 
reach a final concentration of 5*105 cfu/mL and 100 μL in each well. The plates were 
incubated at 37oC for 16-20 hours and read on a Molecular Devices SpectraMax Plus 
384 Microplate reader at λ=600nm. MIC values were defined by the lowest 
concentration to result in >90% growth inhibition.  
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